Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Asston Pharma IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2019 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size 19.75 Cr
Profile
Price Range 115  to  123 per share
Profile
Min Investment ₹123
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Our Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. Our Company operates under brand “Asston”. Presently, our Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc. Apart from manufacturing products for direct sales, our Company also manufactures various pharmaceutical products for different marketers on loan license or on contract manufacturing basis. Our business is primarily conducted on a principle-to-principle basis with various marketers. As on the date, we cater to multiple corporate clients on loan licence and/or contract manufacturing basis. Currently, our Company has its production facility at Ambernath, Maharashtra, for producing generic medicines in the tablet form and nutraceutical medicines in the tablet form, syrup and sachet form. We have a dedicated and separate floors for pharmaceutical products and nutraceutical products respectively as the norms and standards are different for both of them and are governed by FDA and FSSAI respectively. Since the FDA norms for pharmaceutical products are much more stringent, to comply with FDA standards separate guidelines are there to be followed. Facility has total production capacity of up to around 8-9 crore tablets per month. Our Company produces an average of 5-6 crore tablets per month, with production capacity varying based on the weight of the medicines. Higherweight medicines result in lower production quantities and vice versa. The syrup production capacity for nutraceuticals is approximately 37.5 kiloliters per month, while sachet production capacity ranges from 30 to 40 lakh sachets per month, depending on the powder weight per sachet. The facility is certified by relevant authorities and undergoes periodic audits by state and central FDA authorities. It includes a QA/QC unit and a warehouse for storing raw materials and finished goods in designated chambers under controlled conditions. Our Company engages contract manufacturers to produce generic medicines and antibiotics in various forms, including tablets, sachets, syrups, and capsules. All contract manufacturers are WHO-GMP certified to ensure their facilities and processes comply with applicable standards and industry norms. Read More

Basic Info

Face Value 10 per share

Price 115  to  123 per share

P/E (x) 17.8

Sales( Cr.) 25

PAT( Cr.) 4

EPS 6.9

Draft Prospectus

Exchange BSE-SME

Promoter

Company Promoters

Ashish Narayan Sakalkar Saili Jayaram More Sachin Chandrakant Badakh

Pre Issue Share Holding 69.07%

Post Issue Share Holding 50.66%

Listing Details:

Listing Price: 119

Listing Gain: -3.36%

Current Price: 73

Gain On Issue: 73 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Jul 09, 2025
Closing Date Jul 11, 2025
Allotment Jul 14, 2025
Refund Jul 15, 2025
Delivery of Shares Jul 15, 2025
Listing Date Jul 16, 2025

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 2000 246,000
Retail (Max) -- -- --
S-HNI (Min) 1 2000 246,000
S-HNI (Max) 4 8000 984,000
B-HNI (Min) 5 10000 1,230,000

Objective of the Issue

1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit 2. Funding the incremental working capital requirements of our Company 3. Repayment and/or prepayment, in part or full, of certain of our outstanding borrowings availed by our Company 4. General Corporate Purposes

Issue

Category Nos Bid Bid (x)
QIB 425000 36449000 85.8x
NII 435000 113826000 261.7x
Retail 746000 128410000 172.1x
EMP 0 0 0x
Total 1606000 278685000 173.5x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Asston Pharma Profit & Loss

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 10 7 16 25
Other Income 1 1 0 1
Total Income 11 7 16 26
Total Expenditure 10 5 13 19
Operating Profit 1 2 3 7
Interest 0 1 1 1
Depreciation 0 0 0 0
Exceptional Income / Expenses 0 0 0 0
Profit Before Tax 0 1 2 6
Provision for Tax 0 0 0 1
Profit After Tax 0 1 1 4
Adjustments 0 0 0 0
Profit After Adjustments 0 1 1 4
Adjusted Earnings Per Share 0.2 1.9 2.2 6.9

Asston Pharma Balance Sheet

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 1 2 6 11
Minority's Interest 0 0 0 0
Borrowings 1 2 2 2
Other Non-Current Liabilities 0 0 0 0
Total Current Liabilities 8 10 12 15
Total Liabilities 9 14 20 28
Fixed Assets 1 1 1 1
Other Non-Current Assets 1 2 1 0
Total Current Assets 7 11 18 27
Total Assets 9 14 20 28

Asston Pharma Cash Flow

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0
Cash Flow from Operating Activities -1 -0 -4 -0
Cash Flow from Investing Activities -0 -1 -0 1
Cash Flow from Financing Activities 1 1 4 -1
Net Cash Inflow / Outflow 0 -0 -0 0
Closing Cash & Cash Equivalent 0 0 0 0

Asston Pharma Ratios

# Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.2 1.89 2.17 6.9
CEPS(Rs) 0.21 1.95 2.25 7.03
DPS(Rs) 0 0 0 0
Book NAV/Share(Rs) 1.66 3.55 10.19 17.09
Core EBITDA Margin(%) -3.7 23.2 16.33 24.6
EBIT Margin(%) 6.17 32.63 17.64 26.56
Pre Tax Margin(%) 1.66 21.61 11.66 22.76
PAT Margin (%) 1.15 16.16 8.73 17.27
Cash Profit Margin (%) 1.24 16.73 9.05 17.6
ROA(%) 1.17 9.11 8.01 17.89
ROE(%) 11.9 72.49 32.47 50.56
ROCE(%) 13.97 37.2 26.9 42.64
Receivable days 243.49 419.04 289.92 296.65
Inventory Days 19.14 55.94 34.42 15.72
Payable days 246.66 685.4 250.27 190.57
PER(x) 0 0 0 0
Price/Book(x) 0 0 0 0
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 0.4 0.89 0.49 0.53
EV/Core EBITDA(x) 6.45 2.68 2.71 1.98
Net Sales Growth(%) 0 -31.89 138.39 60.65
EBIT Growth(%) 0 260.22 28.89 141.8
PAT Growth(%) 0 855.33 28.74 217.95
EPS Growth(%) 0 855.34 14.96 217.94
Debt/Equity(x) 3.56 2.64 1.07 0.68
Current Ratio(x) 0.98 1.09 1.52 1.8
Quick Ratio(x) 0.91 0.94 1.4 1.75
Interest Cover(x) 1.37 2.96 2.95 7
Total Debt/Mcap(x) 0 0 0 0

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 56% 36% 0% 0%
Operating Profit CAGR 133% 91% 0% 0%
PAT CAGR 300% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR NA% NA% NA% NA%
ROE Average 51% 52% 42% 42%
ROCE Average 43% 36% 30% 30%

Company Contact Information

Asston Pharmaceuticals Ltd.

Vandana Mishra

91 22 49731411

info@asstonpharmaceuticals.com

4th Floor, Office No A-431 Balaji Bhavan, Plot No 42 A Sector-11 Cbd Belapur, Navi Mumbai

IPO Lead Manager(s)

Asston Pharmaceuticals Ltd.

Sobhagya Capital Options Ltd

Registrar Info

Asston Pharmaceuticals Ltd.

Maashitla Securities Pvt Ltd.

451, Krishna Apra Business Square, Netaji Subhash Place, Pitampura, New Delhi – 110034

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!